EMEA-002018-PIP02-16-M05

Table of contents

Key facts

Invented name
Venclyxto
Active substance
Venetoclax
Therapeutic area
  • Haematology-Hemostaseology
  • Oncology
Decision number
P/0148/2022
PIP number
EMEA-002018-PIP02-16-M05
Pharmaceutical form(s)
  • Film-coated tablet
  • Tablet for oral suspension
  • Powder for oral suspension
Condition(s) / indication(s)
  • Treatment of malignant neoplasms of the haematopoietic and lymphoid tissue
  • Treatment of solid malignant tumours
Route(s) of administration
Oral use
Contact for public enquiries
AbbVie Ltd

E-mail: paediatricteam@abbvie.com
Tel. +44(0) 1628925033
Decision type
PM: decision on the application for modification of an agreed PIP

Decision

Related content

How useful was this page?

Add your rating